Patient-Reported Outcomes of Patients With Advanced RCC Treated With…

Northwestern Medicine Oncology and Hematology

D. Cella

Clinical Implications of CheckMate 9ER Data: Applications for Practi…

Rush University Medical Center

A. Tan

ASCO GU 2023 3-Year Follow-Up From The Phase 3 CheckMate 9ER Trial: …

ASCO GU 2023 Conference Coverage

M. Burotto

ASCO® 2023 Summary: "RCC Updates From The Recent Trials"

Dana-Farber Cancer Institute

W. Xu, T. Choueiri

ASCO® 2023 Insights: "Combination Therapies Come of Age in Kidney Ca…

Insights from 2023 ASCO® Annual Meeting

D. Braun

ASCO® 2023 Insights: "HR-QoL Measures in RCC - Patient-Reported Rele…

Insights from 2023 ASCO® Annual Meeting

C. Decat Bergerot

ASCO® 2023 Insights: "Optimizing Therapy Selection for Patients With…

Insights from 2023 ASCO® Annual Meeting

B. McGregor

ASCO® 2023 Insights: "Association of Host Immune Signatures With Res…

Insights from 2023 ASCO® Annual Meeting

E. Saad

Optimal Toxicity Management in mRCC

Kate Young

Dana-Farber Cancer Institute Kidney Cancer Updates From ASCO GU 2023

Dana-Farber Cancer Institute

W. Xu, T. Choueiri

Front-Line Treatment of Renal Cell Carcinoma

Benjamin Garmezy

How to Select Frontline Therapy for Metastatic Clear Cell RCC

Matthew Campbell

ASCO GU 2023 Longitudinal Detection of ctDNA in Patients With Advanc…

ASCO GU 2023 Conference Coverage

A. Basu, C. Park